Authors
Latest:
Dr. Conte on Outcomes With 1 Year Vs 9 Weeks of Adjuvant Trastuzumab in HER2+ Breast CancerPier Franco Conte, MD, discusses long-term outcomes with 1 year vs 9 weeks of treatment with adjuvant trastuzumab in patients with HER2-positive early breast cancer.
Latest:
Dr. Porcu on the Need for Diverse Representation in Clinical TrialsPierluigi Porcu, MD, discusses the need for diverse representation in clinical trials.
Latest:
Dr Sonneveld on the Background of the D-VRd Regimen in Newly Diagnosed MyelomaPieter Sonneveld, MD, PhD, discusses the background of the PERSEUS trial, which evaluated D-VRd for induction and consolidation in newly diagnosed myeloma.
Latest:
Dr. Lugtenburg on Maintenance Rituximab in DLBCLPieternella J. Lugtenburg, MD, PhD, an internist and hematologist at Erasmus Medical Center in Rottenham, Netherlands, discusses the use of rituximab as maintenance therapy in patients with diffuse large B-cell lymphoma.
Latest:
Managing Chemotherapy-Induced Peripheral NeuropathyChemotherapy-induced peripheral neuropathy is a common side effect in patients with cancer and nurses are essential to helping patients to manage this condition.
Latest:
Integrating PARP Inhibitors Into the Treatment of WomenAfter years in development, several PARP inhibitors have achieved indications in ovarian cancer treatment, while others continue in development and expanding indications.
Latest:
News Reports: April 2007News reports featured in this issue: 1) Breast Cancer Spotlight 2) Expert Cancer Centers Cost-Effective for Managing Ovarian Cancer 3) New Breathalyzer
Latest:
Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic CancerAn integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.
Latest:
Dr. Mistry on Gaucher Disease Entering a New EraDr. Pramod Mistry from Yale University School of Medicine on Gaucher Disease Entering a New Era
Latest:
Dr. Patel on the Clinical Implications of Luspatercept Approval in MDSPrapti Patel, MD, discusses the clinical implications of the FDA approval of luspatercept-aamt in myelodysplastic syndrome.
Latest:
Dr. Adusumilli on the Rationale for Mesothelin-Targeted CAR T-Cell TherapyPrasad S. Adusumilli, MD, surgeon, deputy chief of Thoracic Service, co-director of the Mesothelioma Program, head of Solid Tumors Cell Therapy, Cellular Therapeutics Center, at Memorial Sloan Kettering Cancer Center, discusses the rationale for an autologous mesothelin-targeted CAR T-cell therapy in advanced solid tumors.
Latest:
Dr. Adusumilli on the Development of CAR T Cells in Solid TumorsPrasad S. Adusumilli, MD, FACS, discusses the current role of chimeric antigen receptor T-cell therapy as treatment of patients with solid tumors and how this is evolving compared to CAR T cells in hematologic malignancies.
Latest:
Dr. Kapoor on Advice for Oncologists Treating Patients With MyelomaPrashant Kapoor, MD, hematologic oncologist, Mayo Clinic, shares advice for community oncologists who are treating patients with multiple myeloma.
Latest:
Dr. Ramakrishnan on Negative Results of the BELINDA Trial in Non-Hodgkin LymphomaPraveen Ramakrishnan, MD, discusses the negative results from the phase 3 BELINDA trial and its effect on the use of CAR T-cell products in aggressive B-cell non-Hodgkin lymphoma.
Latest:
Future Directions in Chronic GvHDDr. Chaudhary and Dr. Merin discuss potential areas for exploration and unmet needs in the chronic GvHD treatment landscape.
Latest:
Rapid Readouts: Ibrutinib Plus Rituximab and Venetoclax Followed by Risk-Stratified Chemoimmunotherapy in Young Patients With Previously Untreated MCLExpert perspectives on the phase II clinical trial assessing IRV triplet therapy in young patients with previously untreated mantle cell lymphoma to help minimize chemotherapy exposure.
Latest:
Relacorilant Plus Nab-Paclitaxel Carves New Avenues of Platinum-Resistant Ovarian Cancer Care: With Premal Thaker, MD, MSDr Thaker discusses the rationale for combining relacorilant with nab-paclitaxel in platinum-resistant ovarian cancer, and the future of the ROSELLA trial.
Latest:
Dr. Lulla Discusses Post-Transplant Options for LeukemiasPremal Lulla, MD, discusses the need for cellular therapies for patients with leukemia after transplant.
Latest:
Smart Apps for Smart DocsLife as a fellow is extremely hectic, and mobile apps can help us save an enormous amount of time when conducting research.
Latest:
Dr. Deininger on the Role of Genetic Instability in Mutations That Lead to CancerPrescott Deininger, PhD, Professor and Regents Distinguished Chair, director, Tulane Cancer Center, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, discusses how genetic instability plays a role in mutations that may lead to specific tumor types.
Latest:
OncLive Adds UW Carbone Cancer Center to Its Roster of Strategic Alliance PartnersFocus will be on Wisconsin Center's innovative research centers and impact on local communities.
Latest:
Matthew Lara on Younger Vs Older Patients With NSCLCPrimo Lara, MD, and his son, Matthew Stephen Lara, discuss an analysis of predictors of survival for younger patients with non-small cell lung cancer.
Latest:
Dr. Lara on the FDA Approval of Adjuvant Sunitinib in RCCPrimo N. Lara Jr, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the FDA approval of adjuvant sunitinib (Sutent) for high-risk patients with renal cell carcinoma (RCC).
Latest:
Dr. Lara on the Role of Sunitinib for Renal Cell CarcinomaPrimo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the role of sunitinib (Sutent) for patients with renal cell carcinoma (RCC).
Latest:
Future of MFExperts discuss how treatments, either monotherapy or combination, may impact the treatment landscape for MF and how they might choose among the new agents.
Latest:
Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic CancerAn integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.
Latest:
Dr Kumethaker on CSF Tumor Detection in Breast Cancer or NSCLC with Leptomeningeal DiseasePriya U. Kumthekar, MD, discusses the use of a novel diagnostic platform to detect CSF tumor cells in patients with leptomeningeal disease.
Latest:
Cleveland Clinic Researchers Explore Genetic Landscape of Radiotherapeutic ResistancePriyanka Gopal, MD, and Mohamed E. Abazeed, MD, PhD, discuss radiotherapy in the era of precision medicine.
